Valproic-acid-induced thrombocytopenia and hepatotoxicity: discontinuation of treatment?
We report the case of a 4-year-old boy with long-term sodium valproate (valproic acid; VPA) therapy who suddenly developed clinically relevant thrombocytopenia and signs of hepatotoxicity. Reduction of the VPA dosage led to clinical and laboratory parameter improvement, while discontinuation of therapy was not necessary. The current practice of the management of VPA-induced side effects is discussed in view of the current recommendations from the literature.
Lackmann
Gerd-Michael
GM
Outpatient Pediatric Office, Hamburg, Germany. GMLackmann@t-online.de
D000927:Anticonvulsants / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D002675:Child, Preschool; D004829:Epilepsy, Generalized / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D008297:Male; D010976:Platelet Count; D013921:Thrombocytopenia / Q000139:chemically induced*; D014635:Valproic Acid / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use
D000927:Anticonvulsants; D014635:Valproic Acid